Press Releases | Sutro Biopharma, Inc.

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

Events, News, Presentations, Press Releases

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference SOUTH SAN FRANCISCO, Calif., June 18, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...

Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress

News, Press Releases

Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress Interim results show STRO-001 was generally well...

Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress

Events, News, Presentations, Press Releases

Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress SOUTH SAN FRANCISCO, Calif., May 16, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming European Hematology Association...

Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments

News, Press Releases

Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data to be presented at the European Hematology Association (“EHA”) Congress, June...

Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments

News, Press Releases

Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019 STRO-002 Phase 1 Clinical Trial Initiated in Ovarian and...

Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers

Press Releases

Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers STRO-002, Sutro’s second clinical program, is designed to deliver “toxic payloads” to kill cancer cells Sutro plans to enroll up to 160 patients in...

« Older Entries

Next Entries »